Welcome to our dedicated page for Charming Medical news (Ticker: MCTA), a resource for investors and traders seeking the latest updates and insights on Charming Medical stock.
Charming Medical Limited (Nasdaq: MCTA) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products with a focus on women’s health, beauty, and wellness. Its news flow reflects both its role as a TCM-inspired wellness operator and its status as a newly listed company on the Nasdaq Capital Market.
News related to Charming Medical Limited often centers on capital markets milestones and corporate financing events. Recent announcements have covered the pricing and closing of its initial public offering of Class A ordinary shares, the commencement of trading under the symbol MCTA, and the full exercise of the underwriters’ over-allotment option. These updates outline the size of the offering, the structure of the over-allotment, and the company’s stated plans for using the proceeds, including business expansion, potential strategic investments and acquisitions, research and development, and general corporate purposes.
Company news also provides context on Charming Medical Limited’s business model, highlighting its TCM-inspired services such as womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional abdominal binding, as well as its Beauty Lab supplements and beauty products. Announcements describe how the company integrates TCM principles with modern technology and how it extends its wellness philosophy through training, dietary therapy consultancy, and franchise opportunities.
Investors and observers can use this news page to follow key developments in Charming Medical Limited’s public company journey, including offering-related disclosures and other material press releases. Regular visits can help readers monitor how the company pursues its stated growth plans in TCM-inspired women’s wellness and beauty.
Charming Medical (Nasdaq: MCTA) announced full exercise of the underwriters' 15% over-allotment option, adding 240,000 Class A ordinary shares at the public offering price of $4.00 per share. The over-allotment generated gross proceeds of $0.96 million, bringing aggregate gross proceeds from the initial public offering to approximately $7.36 million before underwriting discounts and offering expenses.
The company's Class A ordinary shares began trading on the Nasdaq Capital Market on October 21, 2025. The company said it intends to use net proceeds for business expansion, strategic investments and acquisitions, research and development, and general working capital.
Charming Medical (Nasdaq: MCTA) closed its initial public offering on October 22, 2025, selling 1,600,000 Class A ordinary shares at a public offering price of $4.00 per share for gross proceeds of $6.4 million before underwriting discounts and offering expenses.
The Class A ordinary shares began trading on the Nasdaq Capital Market under the symbol MCTA on October 21, 2025. The company granted underwriters a 45-day over-allotment option to buy up to an additional 240,000 shares (15%), which would raise gross proceeds to approximately $7.36 million if fully exercised.
The company intends to use net proceeds for business and geographic expansion, potential strategic investments and acquisitions, research and development, and general working capital and corporate purposes. The offering was conducted on a firm commitment basis and was declared effective by the SEC on September 30, 2025.
Charming Medical (Nasdaq: MCTA) priced an initial public offering of 1,600,000 Class A ordinary shares at $4.00 per share, with expected gross proceeds of approximately $6.4 million. Shares are expected to begin trading on the Nasdaq Capital Market on October 21, 2025, and the offering is expected to close on or about October 22, 2025, subject to customary closing conditions.
The underwriters have a 45‑day over‑allotment option for an additional 240,000 shares (15%), which would raise gross proceeds to about $7.36 million. Net proceeds are intended for geographic expansion, strategic investments, R&D, and working capital.
FAQ
What is the current stock price of Charming Medical (MCTA)?
What is the market cap of Charming Medical (MCTA)?
